Showing results (171-180 of 181) with videos related to
Sort By:
Pageof 19
International Journal of Medical Informatics|December 6, 2024
Developing a prototype for federated analysis to enhance privacy and enable trustworthy access to COVID-19 research dataSolmaz Eradat Oskoui, Matthew Retford, Eoghan Forde, et al.Journal of Cardiac Failure|August 15, 2025
The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive CardiologyAnuradha Lala, Craig Beavers, Vanessa Blumer, et al.International Journal of Cancer|July 22, 2010
Medical radiation exposure and risk of retinoblastoma resulting from new germline RB1 mutationGreta R Bunin, Marc A Felice, William Davidson, et al.Ophthalmology. Retina|June 12, 2022
The Prevalence of Retinal Disease and Associated CNS Disease in Young Patients with Incontinentia PigmentiIan D Danford, Brittni A Scruggs, Antonio Capone, et al.Ophthalmology. Retina|July 17, 2022
Late Vitreoretinal Complications of Regressed Retinopathy of Prematurity: Retinal Break, Vitreous Hemorrhage, and Retinal DetachmentHan-Tung Hsu, Eugene Yu-Chuan Kang, Michael P Blair, et al.American Journal of Ophthalmology|October 24, 2025
Comparing Rhegmatogenous and Tractional Retinal Detachment in Regressed Retinopathy of Prematurity: An International, Multicenter StudyHan-Tung Hsu, Eugene Yu-Chuan Kang, Michael P Blair, et al.Ophthalmology|July 12, 2021
International Classification of Retinopathy of Prematurity, Third EditionMichael F Chiang, Graham E Quinn, Alistair R Fielder, et al.Nature|August 9, 2016
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sicknessShilpi Khare, Advait S Nagle, Agnes Biggart, et al.Journal of Medicinal Chemistry|July 16, 2020
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of LeishmaniasesAdvait Nagle, Agnes Biggart, Celine Be, et al.Journal of Medicinal Chemistry|May 19, 2026
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical ValidationDean P Phillips, Phil B Alper, Charles Y Cho, et al.Pageof 19